<DOC>
	<DOCNO>NCT03062865</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) complex multifactorial autoimmune disease . The biological treatment currently available treatment RA TNF-alpha inhibitor . Tumor necrosis factor ( TNF ) dominant cytokine inflammatory process rheumatoid arthritis . The anti-TNFs first enter market , revolutionised prognosis patient RA . They remain common first-line biotherapy use time . The French Society Rheumatologists intend coordinate prospective national registry study follow-up . This registry include 1500 RA patient start treatment anti-TNF-Î± follow 5 year , regardless therapeutic modification occur thereafter . This registry observational , multicentre , longitudinal , prospective registry study The objective registry contribute 1 ) evaluate therapeutic management patient ; 2 ) improve therapeutic management .</brief_summary>
	<brief_title>French National Registry : ART REGISTRY ( Observational Study )</brief_title>
	<detailed_description>Design : Observational , multicentre , longitudinal , prospective registry Primary objective : To evaluate real life efficacy safety anti-TNF inhibitor patient RA use prospective national registry . Target population : Patients initiate anti-TNF therapy RA ( include infliximab , adalimumab , etanercept , certolizumab golimumab , respective biosimilar accord arrival market ) Number patient centre : More 80 center France ( hospital-based , public private practice ) Recruitment period : 3 year Follow-up : 5 year</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient RA , Patient specialist physician decide start treatment antiTNF drug , regardless treatment line regardless antiTNF , include infliximab , adalimumab , etanercept , certolizumab golimumab , respective biosimilar accord arrival market Clinicians ( hospitalbased private practice ) agree adhere yearly renewal hospital prescription Patient already treat antiTNF past ( drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid arthritis ( RA )</keyword>
	<keyword>TNF-alpha inhibitor</keyword>
</DOC>